IMAC Holdings, Inc.
IMACW
NASDAQ Capital Market0.01
USD
+0.00
- -
IMAC Holdings, Inc.
IMACW
(NASDAQ Capital Market)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- IMAC Holdings, Inc. (NASDAQ: BACK; Warrants: IMACW) operates as a holding company focused on precision medicine services through its subsidiary Ignite Proteomics LLC; the company provides proteomic products based on activated protein analysis, including a proprietary reverse phase protein array (RPPA) platform that quantifies protein signaling across 32 analytes to support oncology clinical treatment decisions, particularly for advanced breast cancer, and biopharmaceutical drug development in immuno-oncology; services encompass pathway-based assessments using RPPA and laser capture microdissection (LCM) for therapeutic development from discovery through clinical trials, targeting oncologists and drug developers in the United States. IMAC Holdings was founded in 2000 and maintains headquarters in Franklin, Tennessee. In May 2024, the company acquired key assets from Theralink Technologies, Inc. in a settlement resolving outstanding debt, terminating a prior merger agreement and enabling direct integration of Theralink's breast cancer diagnostics advancements into IMAC's precision medicine operations, including transition of key personnel; in September 2025, Ignite Proteomics announced a significant research collaboration with Inova Health System to apply RPPA technology to tumor samples from late-stage gastrointestinal cancer patients, marking one of the subsidiary's largest service agreements to date and contributing to 2025 revenue growth. The company operates within the biotechnology and pharmaceuticals sector, emphasizing non-opioid, innovative solutions in oncology; prior activities in orthopedic and regenerative therapies have shifted toward this core precision oncology focus.